The Aftermath of a 'Miracle Cure' for a Rare Cancer
By James Tabery,
Wired
| 09. 04. 2023
You really can't understand all the excitement surrounding personalized medicine without knowing a little bit about Gleevec. And once you know the full story of Gleevec, you really can’t help but see much of that excitement as wild and even dangerous exaggeration.
Personalized medicine (sometimes it’s also called “precision medicine”) works by tailoring health care to our genomes. Traditional, one-size-fits-all medicine, the criticism goes, treats us all as if we’re the same, but personalized medicine tracks the molecular-genetic differences between us to deliver the right treatment, to the right patient, at the right time. The approach has gotten its most purchase in the management of cancers and rare diseases, but champions foresee a future where it spreads out across all facets of health care, revolutionizing the treatment of everything from diabetes and cardiovascular disease to asthma and rheumatoid arthritis. A big part of the enthusiasm is economic in nature. Rather than sending patients off on costly and frustrating trial-and-error odysseys, advocates of precision medicine see its ability to find the right gene-treatment matches from the beginning of care...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...